Search - tctmd.com

Displaying 121 - 140 of 179

Sort: Relevancy | Date

Clopidogrel-Aspirin in Minor Stroke/TIA of Maximum Benefit in First 21 Days

News Daily News

Clopidogrel-Aspirin in Minor Stroke/TIA of Maximum Benefit in First 21 Days

July 09, 2019

Which ASCVD Patients Will Benefit Most From Rivaroxaban Plus Aspirin? Some Clues

News Daily News

Which ASCVD Patients Will Benefit Most From Rivaroxaban Plus Aspirin? Some Clues

June 26, 2019

Ischemic Events Worsen Long-term Cognitive Decline

News Daily News

Ischemic Events Worsen Long-term Cognitive Decline

Yael L. Maxwell

June 18, 2019

Absence of FH Diagnosis Linked to Increased Risk of Premature Mortality

News Conference News EAS 2019

Absence of FH Diagnosis Linked to Increased Risk of Premature Mortality

Michael O'Riordan

June 05, 2019

Bariatric Surgery Linked to Survival Advantage After MI and CVA

News Daily News

Bariatric Surgery Linked to Survival Advantage After MI and CVA

Michael O'Riordan

May 13, 2019

Most STEMI Patients Head to ICU After PCI, but Not All Need to Go

News Daily News

Most STEMI Patients Head to ICU After PCI, but Not All Need to Go

Michael O'Riordan

April 15, 2019

New Genetic Evidence Shows Alcoholic Drinks Don’t Cut Stroke Risk

News Daily News

New Genetic Evidence Shows Alcoholic Drinks Don’t Cut Stroke Risk

Yael L. Maxwell

April 09, 2019

Final ANNEXA-4 Results Published, Confirm Rapid Andexanet Alfa Effects

News Conference News ISC 2019

Final ANNEXA-4 Results Published, Confirm Rapid Andexanet Alfa Effects

February 13, 2019

Working Less, Earning Less: Stroke, MI, and Cardiac Arrest Have Long-term Labor Consequences

News Daily News

Working Less, Earning Less: Stroke, MI, and Cardiac Arrest Have Long-term Labor Consequences

Michael O'Riordan

January 07, 2019

Man’s Best Friend, Especially After an MI or Stroke

News Conference News WCC 2018

Man’s Best Friend, Especially After an MI or Stroke

December 11, 2018

Alirocumab Should Be Priced at $6,300 Annually: ODYSSEY Cost-Effectiveness Study

News Conference News AHA 2018

Alirocumab Should Be Priced at $6,300 Annually: ODYSSEY Cost-Effectiveness Study

Michael O'Riordan

November 15, 2018

ODYSSEY Outcomes Published as New Cholesterol Guidelines Loom

News Daily News

ODYSSEY Outcomes Published as New Cholesterol Guidelines Loom

Michael O'Riordan

November 07, 2018

Aspirin Fails to Prevent CV Events in People at ‘Moderate’ Risk of Disease: ARRIVE

News Conference News ESC 2018

Aspirin Fails to Prevent CV Events in People at ‘Moderate’ Risk of Disease: ARRIVE

August 26, 2018

MARINER Fails to Meet Primary Endpoint Testing Rivaroxaban for Extended VTE Thromboprophylaxis

News Conference News ESC 2018

MARINER Fails to Meet Primary Endpoint Testing Rivaroxaban for Extended VTE Thromboprophylaxis

August 26, 2018

Hospital Readmissions at 30 Days Declining for Stroke Patients

News Daily News

Hospital Readmissions at 30 Days Declining for Stroke Patients

Michael O'Riordan

August 20, 2018

IV Alteplase No Help for Minor, Nondisabling Strokes in PRISMS Trial

News Daily News

IV Alteplase No Help for Minor, Nondisabling Strokes in PRISMS Trial

July 11, 2018

New Biomarker on the Block, FGF-23, May Aid in Secondary-Event Prediction Following ACS

News Daily News

New Biomarker on the Block, FGF-23, May Aid in Secondary-Event Prediction Following ACS

Yael L. Maxwell

April 18, 2018

ACC 2018, Day Two: Antiplatelets in ACS, Dabigatran in Noncardiac Surgery, and More

News Conference News ACC 2018

ACC 2018, Day Two: Antiplatelets in ACS, Dabigatran in Noncardiac Surgery, and More

March 11, 2018

ACC 2018: More PCSK9 Outcomes, Antiplatelet Insights, and LifeVest Data at Last

News Conference News ACC 2018

ACC 2018: More PCSK9 Outcomes, Antiplatelet Insights, and LifeVest Data at Last

March 05, 2018

De-escalating DAPT to a Clopidogrel-Based Strategy After PCI for ACS Gets Boost in TOPIC-VASP

News Daily News

De-escalating DAPT to a Clopidogrel-Based Strategy After PCI for ACS Gets Boost in TOPIC-VASP

Yael L. Maxwell

January 04, 2018

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.